Morin inhibits STAT3 tyrosine 705 phosphorylation in tumor cells through activation of protein tyrosine phosphatase SHP1

Biochemical Pharmacology

Volumn 85, Issue 7, 2013, Pages 898-912

  Gupta, Subash C ^a   Phromnoi, Kanokkarn ^a   Aggarwal, Bharat B ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Apoptosis; Chemosensitization; Flavonol; SHP 1; STAT3

Indexed keywords

BORTEZOMIB; CASPASE 8; CASPASE 9; FLICE INHIBITORY PROTEIN; GALANGIN; JANUS KINASE 1; JANUS KINASE 2; KAEMPFEROL; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MORIN; MYRICETIN; PERVANADATE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN TYROSINE PHOSPHATASE SHP 1; QUERCETIN; STAT3 PROTEIN; SURVIVIN; THALIDOMIDE; X LINKED INHIBITOR OF APOPTOSIS;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CELL VIABILITY; CHEMOSENSITIZATION; CORRELATION ANALYSIS; DNA BINDING; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; GENE SILENCING; GROWTH; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR CELL; UPREGULATION;

ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; FLAVONOIDS; HEAD AND NECK NEOPLASMS; HUMANS; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP; TYROSINE;

EID: 84874651128     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.12.018     Document Type: Article

References (64)

1. B.B. Aggarwal, and S. Shishodia Molecular targets of dietary agents for prevention and therapy of cancer Biochem Pharmacol 71 2006 1397 1421
2. J. Brown, J. O'Prey, and P.R. Harrison Enhanced sensitivity of human oral tumours to the flavonol, morin, during cancer progression: involvement of the Akt and stress kinase pathways Carcinogenesis 24 2003 171 177 (Pubitemid 36267083)
3. S.K. Manna, R.S. Aggarwal, G. Sethi, B.B. Aggarwal, and G.T. Ramesh Morin (3,5,7,2′,4′-pentahydroxyflavone) abolishes nuclear factor-kappaB activation induced by various carcinogens and inflammatory stimuli, leading to suppression of nuclear factor-kappaB-regulated gene expression and up-regulation of apoptosis Clin Cancer Res 13 2007 2290 2297 (Pubitemid 46649899)
4. Y.C. Chen, S.C. Shen, J.M. Chow, C.H. Ko, and S.W. Tseng Flavone inhibition of tumor growth via apoptosis in vitro and in vivo Int J Oncol 25 2004 661 670
5. S.H. Fang, Y.C. Hou, W.C. Chang, S.L. Hsiu, P.D. Chao, and B.L. Chiang Morin sulfates/glucuronides exert anti-inflammatory activity on activated macrophages and decreased the incidence of septic shock Life Sci 74 2003 743 756
6. C.Y. Hsiang, S.L. Wu, and T.Y. Ho Morin inhibits 12-O- tetradecanoylphorbol-13-acetate-induced hepatocellular transformation via activator protein 1 signaling pathway and cell cycle progression Biochem Pharmacol 69 2005 1603 1611
7. V. Sreedharan, K.K. Venkatachalam, and N. Namasivayam Effect of morin on tissue lipid peroxidation and antioxidant status in 1,2-dimethylhydrazine induced experimental colon carcinogenesis Invest New Drugs 27 2009 21 30
8. P. Thuillier, A.R. Brash, J.P. Kehrer, J.B. Stimmel, L.M. Leesnitzer, and P. Yang Inhibition of peroxisome proliferator-activated receptor (PPAR)-mediated keratinocyte differentiation by lipoxygenase inhibitors Biochem J 366 2002 901 910
9. V. Sivaramakrishnan, and S. Niranjali Devaraj Morin regulates the expression of NF-kappaB-p65, COX-2 and matrix metalloproteinases in diethylnitrosamine induced rat hepatocellular carcinoma Chem Biol Interact 180 2009 353 359
10. B.B. Aggarwal, G. Sethi, K.S. Ahn, S.K. Sandur, M.K. Pandey, and A.B. Kunnumakkara Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution Ann N Y Acad Sci 1091 2006 151 169 (Pubitemid 47092233)
11. R. Catlett-Falcone, T.H. Landowski, M.M. Oshiro, J. Turkson, A. Levitzki, and R. Savino Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells Immunity 10 1999 105 115 (Pubitemid 29077388)
12. X. Cao, A. Tay, G.R. Guy, and Y.H. Tan Activation and association of Stat3 with Src in v-Src-transformed cell lines Mol Cell Biol 16 1996 1595 1603 (Pubitemid 26095631)
13. S.C. Gupta, R. Kannappan, S. Reuter, J.H. Kim, and B.B. Aggarwal Chemosensitization of tumors by resveratrol Ann N Y Acad Sci 1215 2011 150 160
14. N. Sato, T. Yamamoto, Y. Sekine, T. Yumioka, A. Junicho, and H. Fuse Involvement of heat-shock protein 90 in the interleukin-6-mediated signaling pathway through STAT3 Biochem Biophys Res Commun 300 2003 847 852 (Pubitemid 36259839)
15. S. Ito, T. Oyake, K. Murai, and Y. Ishida Deguelin suppresses cell proliferation via the inhibition of survivin expression and STAT3 phosphorylation in HTLV-1-transformed T cells Leuk Res 34 2010 352 357
16. J. Chung, E. Uchida, T.C. Grammer, and J. Blenis STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation Mol Cell Biol 17 1997 6508 6516 (Pubitemid 27451197)
17. H. Jiao, K. Berrada, W. Yang, M. Tabrizi, L.C. Platanias, and T. Yi Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1 Mol Cell Biol 16 1996 6985 6992 (Pubitemid 26389758)
18. C.D. Chung, J. Liao, B. Liu, X. Rao, P. Jay, and P. Berta Specific inhibition of Stat3 signal transduction by PIAS3 Science 278 1997 1803 1805 (Pubitemid 27527648)
19. M.S. Raab, K. Podar, I. Breitkreutz, P.G. Richardson, and K.C. Anderson Multiple myeloma Lancet 374 2009 324 339
20. K. Nilsson, H. Bennich, S.G. Johansson, and J. Ponten Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient Clin Exp Immunol 7 1970 477 489
21. M. Kawano, T. Hirano, T. Matsuda, T. Taga, Y. Horii, and K. Iwato Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas Nature 332 1988 83 85
22. C.L. Yu, D.J. Meyer, G.S. Campbell, A.C. Larner, C. Carter-Su, and J. Schwartz Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein Science 269 1995 81 83
23. K.S. Ahn, G. Sethi, B. Sung, A. Goel, R. Ralhan, and B.B. Aggarwal Guggulsterone, a farnesoid X receptor antagonist, inhibits constitutive and inducible STAT3 activation through induction of a protein tyrosine phosphatase SHP-1 Cancer Res 68 2008 4406 4415
24. Z. Li, M. Xu, S. Xing, W.T. Ho, T. Ishii, and Q. Li Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth J Biol Chem 282 2007 3428 3432 (Pubitemid 47084420)
25. S.C. Gupta, S. Prasad, S. Reuter, R. Kannappan, V.R. Yadav, and J. Ravindran Modification of cysteine 179 of IkappaBalpha kinase by nimbolide leads to down-regulation of NF-kappaB-regulated cell survival and proliferative proteins and sensitization of tumor cells to chemotherapeutic agents J Biol Chem 285 2010 35406 35417
26. S.C. Gupta, S. Reuter, K. Phromnoi, B. Park, P.S. Hema, and M. Nair Nimbolide sensitizes human colon cancer cells to TRAIL through reactive oxygen species- and ERK-dependent up-regulation of death receptors, p53, and Bax J Biol Chem 286 2011 1134 1146
27. K. Selvendiran, H. Koga, T. Ueno, T. Yoshida, M. Maeyama, and T. Torimura Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor potential of flavonoids Cancer Res 66 2006 4826 4834
28. Y. Han, H.M. Amin, B. Franko, C. Frantz, X. Shi, and R. Lai Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma Blood 108 2006 2796 2803
29. P.R. Greipp, J. San Miguel, B.G. Durie, J.J. Crowley, B. Barlogie, and J. Blade International staging system for multiple myeloma J Clin Oncol 23 2005 3412 3420
30. J.B. Bartlett, K. Dredge, and A.G. Dalgleish The evolution of thalidomide and its IMiD derivatives as anticancer agents Nat Rev Cancer 4 2004 314 322 (Pubitemid 38525287)
31. N. Mitsiades, C.S. Mitsiades, P.G. Richardson, V. Poulaki, Y.T. Tai, and D. Chauhan The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications Blood 101 2003 2377 2380 (Pubitemid 36302084)
32. S. Alas, and B. Bonavida Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis Clin Cancer Res 9 2003 316 326 (Pubitemid 36109748)
33. T. Bowman, R. Garcia, J. Turkson, and R. Jove STATs in oncogenesis Oncogene 19 2000 2474 2488 (Pubitemid 30339203)
34. M.M. Oshiro, T.H. Landowski, R. Catlett-Falcone, L.A. Hazlehurst, M. Huang, and R. Jove Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells Clin Cancer Res 7 2001 4262 4271 (Pubitemid 34044653)
35. T.S. Migone, J.X. Lin, A. Cereseto, J.C. Mulloy, J.J. O'Shea, and G. Franchini Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I Science 269 1995 79 81
36. M. Saydmohammed, D. Joseph, and V. Syed Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells J Cell Biochem 110 2010 447 456
37. T. Tenev, S.A. Bohmer, R. Kaufmann, S. Frese, T. Bittorf, and T. Beckers Perinuclear localization of the protein-tyrosine phosphatase SHP-1 and inhibition of epidermal growth factor-stimulated STAT1/3 activation in A431 cells Eur J Cell Biol 79 2000 261 271 (Pubitemid 30232571)
38. H. Kim, and H. Baumann Dual signaling role of the protein tyrosine phosphatase SHP-2 in regulating expression of acute-phase plasma proteins by interleukin-6 cytokine receptors in hepatic cells Mol Cell Biol 19 1999 5326 5338 (Pubitemid 29339892)
39. T. Yamamoto, N. Sato, Y. Sekine, T. Yumioka, S. Imoto, and A. Junicho Molecular interactions between STAT3 and protein inhibitor of activated STAT3, and androgen receptor Biochem Biophys Res Commun 306 2003 610 615 (Pubitemid 36683119)
40. S. Sun, and B.M. Steinberg PTEN is a negative regulator of STAT3 activation in human papillomavirus-infected cells J Gen Virol 83 2002 1651 1658 (Pubitemid 34716270)
41. J.J. Gunaje, and G.J. Bhat Involvement of tyrosine phosphatase PTP1D in the inhibition of interleukin-6-induced Stat3 signaling by alpha-thrombin Biochem Biophys Res Commun 288 2001 252 257 (Pubitemid 32999754)
42. J. Irie-Sasaki, T. Sasaki, W. Matsumoto, A. Opavsky, M. Cheng, and G. Welstead CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling Nature 409 2001 349 354 (Pubitemid 32151240)
43. N. Tanuma, K. Nakamura, H. Shima, and K. Kikuchi Protein-tyrosine phosphatase PTPepsilon C inhibits Jak-STAT signaling and differentiation induced by interleukin-6 and leukemia inhibitory factor in M1 leukemia cells J Biol Chem 275 2000 28216 28221
44. C.S. Chim, T.K. Fung, W.C. Cheung, R. Liang, and Y.L. Kwong SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway Blood 103 2004 4630 4635 (Pubitemid 38745995)
45. D. Banville, R. Stocco, and S.H. Shen Human protein tyrosine phosphatase 1C (PTPN6) gene structure: alternate promoter usage and exon skipping generate multiple transcripts Genomics 27 1995 165 173
46. A. Martin, H.W. Tsui, M.J. Shulman, D. Isenman, and F.W. Tsui Murine SHP-1 splice variants with altered Src homology 2 (SH2) domains. Implications for the SH2-mediated intramolecular regulation of SHP-1 J Biol Chem 274 1999 21725 21734
47. M. Schwickart, X. Huang, J.R. Lill, J. Liu, R. Ferrando, and D.M. French Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival Nature 463 2010 103 107
48. M. Romagnoli, C. Seveno, S. Wuilleme-Toumi, M. Amiot, R. Bataille, and S. Minvielle The imbalance between Survivin and Bim mediates tumour growth and correlates with poor survival in patients with multiple myeloma Br J Haematol 145 2009 180 189
49. D.S. Siegel, X. Zhang, R. Feinman, T. Teitz, A. Zelenetz, and V.M. Richon Hexamethylene bisacetamide induces programmed cell death (apoptosis) and down-regulates BCL-2 expression in human myeloma cells Proc Natl Acad Sci USA 95 1998 162 166 (Pubitemid 28103924)
50. Y. Tu, S. Renner, F. Xu, A. Fleishman, J. Taylor, and J. Weisz BCL-X expression in multiple myeloma: possible indicator of chemoresistance Cancer Res 58 1998 256 262 (Pubitemid 28047064)
51. G. Desplanques, N. Giuliani, R. Delsignore, V. Rizzoli, R. Bataille, and S. Barille-Nion Impact of XIAP protein levels on the survival of myeloma cells Haematologica 94 2009 87 93
52. M. Romagnoli, V. Trichet, C. David, M. Clement, P. Moreau, and R. Bataille Significant impact of survivin on myeloma cell growth Leukemia 21 2007 1070 1078 (Pubitemid 46672084)
53. Z. You, H. Ouyang, D. Lopatin, P.J. Polver, and C.Y. Wang Nuclear factor-kappa B-inducible death effector domain-containing protein suppresses tumor necrosis factor-mediated apoptosis by inhibiting caspase-8 activity J Biol Chem 276 2001 26398 26404
54. R. Piva, P. Gianferretti, A. Ciucci, R. Taulli, G. Belardo, and M.G. Santoro 15-Deoxy-delta 12,14-prostaglandin J2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF-kappa B activity and down-regulation of antiapoptotic proteins Blood 105 2005 1750 1758 (Pubitemid 40223699)
55. V.N. Ivanov, A. Bhoumik, M. Krasilnikov, R. Raz, L.B. Owen-Schaub, and D. Levy Cooperation between STAT3 and c-jun suppresses Fas transcription Mol Cell 7 2001 517 528 (Pubitemid 32706344)
56. X. Troussard, H. Avet-Loiseau, M. Macro, M.P. Mellerin, M. Malet, and M. Roussel Cyclin D1 expression in patients with multiple myeloma Hematol J 1 2000 181 185
57. C. Greco, I. D'Agnano, G. Vitelli, R. Vona, M. Marino, and M. Mottolese c-MYC deregulation is involved in melphalan resistance of multiple myeloma: role of PDGF-BB Int J Immunopathol Pharmacol 19 2006 67 79
58. D.H. Yang, J.S. Park, C.J. Jin, H.K. Kang, J.H. Nam, and J.H. Rhee The dysfunction and abnormal signaling pathway of dendritic cells loaded by tumor antigen can be overcome by neutralizing VEGF in multiple myeloma Leuk Res 33 2009 665 670
59. K. Phromnoi, S. Prasad, S.C. Gupta, R. Kannappan, S. Reuter, and P. Limtrakul Dihydroxypentamethoxyflavone down-regulates constitutive and inducible signal transducers and activators of transcription-3 through the induction of tyrosine phosphatase SHP-1 Mol Pharmacol 80 2011 889 899
60. F. Yang, V. Jove, H. Xin, M. Hedvat, T.E. Van Meter, and H. Yu Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways Mol Cancer Res 8 2010 35 45
61. G. Muthian, and J.J. Bright Quercetin, a flavonoid phytoestrogen, ameliorates experimental allergic encephalomyelitis by blocking IL-12 signaling through JAK-STAT pathway in T lymphocyte J Clin Immunol 24 2004 542 552 (Pubitemid 39221672)
62. T. Kumamoto, M. Fujii, and D.X. Hou Myricetin directly targets JAK1 to inhibit cell transformation Cancer Lett 275 2009 17 26
63. T.W. Wu, L.H. Zeng, J. Wu, and K.P. Fung Morin hydrate is a plant-derived and antioxidant-based hepatoprotector Life Sci 53 1993 PL213 PL218
64. Z. Yu, W.P. Fong, and C.H. Cheng The dual actions of morin (3,5,7,2′,4′-pentahydroxyflavone) as a hypouricemic agent: uricosuric effect and xanthine oxidase inhibitory activity J Pharmacol Exp Ther 316 2006 169 175 (Pubitemid 43000578)